Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoid

Lymphoma, Follicular

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

33 enrolled

Lymphoid

Lymphoma, Follicular

NCT06350318 2026-02-05

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Phase 2 Recruiting

43 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06492837 2026-01-28

FIL_MOZART

Phase 2 Recruiting

56 enrolled

Lymphoid

Lymphoma, Follicular

NCT04172246 2025-11-21

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase 1/2 Completed

55 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05326308 2025-09-23

ARIADNE

Recruiting

705 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07126678 2025-08-17

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Phase NA Recruiting

15 enrolled

Lymphoid

Lymphoma, Follicular

NCT06859008 2025-08-05

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06959732 2025-05-07

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, Follicular

Clinical Trials

MAHOGANY

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Epco, Zanu, Ritux for R/R FL or MZL

ROSEWOOD

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

FIL_MOZART

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

ARIADNE

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Zanubrutinib Combined With G-CVP in Previously Untreated FL